section name header

Pronunciation

VEL-a-GLOO-ser-ase AL-fa

Classifications

Therapeutic Classification: replacement enzyme

Pharmacologic Classification: enzymes

Indications

REMS


Action

  • Prevents the accumulation of glucocerebrosidases in cells. Replaces glucocerebrosidases that are deficient in type 1 Gaucher disease. Replaces the deficient enzyme in type 1 Gaucher disease.
Therapeutic effects:
  • Improvement in symptoms of Gaucher disease (anemia, thrombocytopenia, bone disease, splenomegaly, and hepatomegaly).

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 11–12 min.

Time/Action Profile

ROUTEONSETPEAKDURATION
IVunknownunknownunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Vpriv